(+)-catechin multiple interactions ISO RGD:731686 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA CTD PMID:25663641 (+)-epicatechin-3-O-gallate multiple interactions ISO RGD:731686 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA CTD PMID:25663641 (+)-Tetrandrine increases glutathionylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased glutathionylation of tetrandrine CTD PMID:21992520 (+)-Tetrandrine multiple interactions ISO RGD:1348646 6480464 CYP3A5 protein promotes the reaction [tetrandrine results in decreased abundance of Glutathione] more ... CTD PMID:26302866 (+)-Tetrandrine increases response to substance ISO RGD:1348646 6480464 CYP3A5 protein results in increased susceptibility to tetrandrine CTD PMID:26302866 (-)-epigallocatechin 3-gallate multiple interactions ISO RGD:731686 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA CTD PMID:25663641 (R,R,R)-alpha-tocopherol increases expression ISO RGD:731686 6480464 alpha-Tocopherol results in increased expression of CYP3A13 mRNA, alpha-Tocopherol results in increased expression of CYP3A13 protein CTD PMID:26102010 (R,R,R)-alpha-tocopherol multiple interactions ISO RGD:1348646 6480464 alpha-Tocopherol inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Testosterone] CTD PMID:31102695 1,1,1-Trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of 1 more ... CTD PMID:12167570 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane increases expression ISO RGD:1348646 6480464 o, p'-DDT results in increased expression of CYP3A11 mRNA CTD PMID:17035600 1,2-dichloroethane increases expression ISO RGD:731686 6480464 ethylene dichloride results in increased expression of CYP3A13 mRNA CTD PMID:28960355 1,2-dimethylhydrazine decreases expression ISO RGD:731686 6480464 1, 2-Dimethylhydrazine results in decreased expression of CYP3A13 mRNA CTD PMID:22206623 1,4-naphthoquinone increases abundance ISO RGD:1348646 6480464 CYP3A5 protein results in increased abundance of 1, 4-naphthoquinone CTD PMID:16243959 1,8-cineole increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Eucalyptol CTD PMID:15715982 1-hydroxymidazolam increases chemical synthesis ISO RGD:1348646 6480464 CYP3A5 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam CTD PMID:18191104 , PMID:26958860 1-hydroxymidazolam multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam, erdafitinib inhibits the reaction [[CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam] CTD PMID:34189909 1-naphthol increases abundance ISO RGD:1348646 6480464 CYP3A5 protein results in increased abundance of 1-naphthol CTD PMID:16243959 1-naphthyl isothiocyanate decreases expression EXP 6480464 1-Naphthylisothiocyanate results in decreased expression of CYP3A9 mRNA CTD PMID:25380136 , PMID:30723492 17alpha-ethynylestradiol increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Ethinyl Estradiol CTD PMID:15304426 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of CYP3A13 mRNA CTD PMID:17108234 17beta-estradiol multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYP3A9 mRNA CTD PMID:32741896 17beta-estradiol 3-benzoate multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYP3A9 mRNA CTD PMID:32741896 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:731686 6480464 2 more ... CTD PMID:21851831 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions EXP 6480464 [3 more ... CTD PMID:16984957 2,2',4,4',5,5'-hexachlorobiphenyl increases expression ISO RGD:731686 6480464 2 more ... CTD PMID:21851831 2,2',4,4'-Tetrabromodiphenyl ether increases expression EXP 6480464 2 more ... CTD PMID:20566336 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of CYP3A13 mRNA, Tetrachlorodibenzodioxin results in decreased expression of CYP3A9 mRNA CTD PMID:16054898 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:731686 6480464 Tetrachlorodibenzodioxin affects the expression of CYP3A13 mRNA CTD PMID:21570461 , PMID:26377647 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:731686 6480464 Tetrachlorodibenzodioxin results in decreased expression of CYP3A13 mRNA CTD PMID:16984957 more ... 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1348646 6480464 Tetrachlorodibenzodioxin results in increased expression of CYP3A5 mRNA CTD PMID:20106945 more ... 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:731686 6480464 2 more ... CTD PMID:16214954 more ... 2,4,6-trinitrobenzenesulfonic acid decreases expression ISO RGD:731686 6480464 Trinitrobenzenesulfonic Acid results in decreased expression of CYP3A13 mRNA CTD PMID:17982090 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of CYP3A13 mRNA CTD PMID:21346803 2,6-di-tert-butyl-4-methylphenol increases expression EXP 6480464 Butylated Hydroxytoluene results in increased expression of CYP3A9 mRNA CTD PMID:18539377 2,6-dinitrotoluene affects expression EXP 6480464 2, 6-dinitrotoluene affects the expression of CYP3A13 mRNA CTD PMID:21346803 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile decreases activity ISO RGD:1348646 6480464 Verapamil results in decreased activity of CYP3A5 protein CTD PMID:15689501 2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile decreases expression EXP 6480464 Verapamil results in decreased expression of CYP3A9 mRNA CTD PMID:17973928 3,3',4,4',5-pentachlorobiphenyl decreases expression EXP 6480464 3 more ... CTD PMID:20959002 3,3',4,4',5-pentachlorobiphenyl multiple interactions EXP 6480464 [3 more ... CTD PMID:16984957 3-methylcholanthrene increases expression ISO RGD:1348646 6480464 Methylcholanthrene results in increased expression of CYP3A5 mRNA CTD PMID:33408298 3-methylcholanthrene multiple interactions ISO RGD:1348646 6480464 AHR protein affects the reaction [Methylcholanthrene results in increased expression of CYP3A5 mRNA] CTD PMID:33408298 4'-tert-Butyl-2',6'-dimethyl-3',5'-dinitroacetophenone increases expression ISO RGD:731686 6480464 musk ketone results in increased expression of CYP3A9 mRNA CTD PMID:9441723 4,4'-diaminodiphenylmethane decreases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of CYP3A9 mRNA CTD PMID:25380136 4,4'-diaminodiphenylmethane increases expression ISO RGD:731686 6480464 4, 4'-diaminodiphenylmethane results in increased expression of CYP3A13 mRNA CTD PMID:18648102 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1 more ... CTD PMID:29285606 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1, 2-diphenyl-1-butene CTD PMID:29285606 4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol increases abundance ISO RGD:1348646 6480464 CYP3A5 protein results in increased abundance of 1-(4-hydroxyphenyl)-1, 2-diphenyl-1-butene CTD PMID:29285606 4-Hydroxy-N-desmethyltamoxifen increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of 4-hydroxy-N-desmethyltamoxifen CTD PMID:29285606 4-Hydroxy-N-desmethyltamoxifen multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of 4-hydroxy-N-desmethyltamoxifen] which results in increased abundance of 4-hydroxy-N-desmethyltamoxifen metabolite CTD PMID:29285606 4-hydroxymidazolam increases chemical synthesis ISO RGD:1348646 6480464 CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam CTD PMID:18191104 4-hydroxymidazolam multiple interactions ISO RGD:1348646 6480464 diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam], Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] CTD PMID:18191104 4-hydroxyphenyl retinamide increases expression ISO RGD:731686 6480464 Fenretinide results in increased expression of CYP3A7 mRNA CTD PMID:28973697 5-aza-2'-deoxycytidine multiple interactions ISO RGD:1348646 6480464 Decitabine inhibits the reaction [Smoke results in decreased expression of CYP3A5 mRNA] CTD PMID:21095227 5-hydroxydiclofenac multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 5-hydroxydiclofenac CTD PMID:24246759 5-Hydroxythalidomide multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide, CYP3A5 protein results in increased oxidation of and results in increased glutathionylation of 5-hydroxythalidomide CTD PMID:20443640 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole affects expression EXP 6480464 Omeprazole affects the expression of CYP3A9 mRNA CTD PMID:19483382 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole increases expression ISO RGD:1348646 6480464 Omeprazole results in increased expression of CYP3A5 mRNA CTD PMID:19118567 6-propyl-2-thiouracil affects expression EXP 6480464 Propylthiouracil affects the expression of CYP3A9 mRNA CTD PMID:19483382 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of CYP3A9 mRNA CTD PMID:24780913 , PMID:25825206 6beta-hydroxytestosterone increases chemical synthesis ISO RGD:1348646 6480464 CYP3A5 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone CTD PMID:26239802 6beta-hydroxytestosterone multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone more ... CTD PMID:26239802 more ... 8-Br-cAMP decreases expression ISO RGD:1348646 6480464 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CYP3A5 mRNA CTD PMID:22079614 acetamide decreases expression EXP 6480464 acetamide results in decreased expression of CYP3A9 mRNA CTD PMID:31881176 aconitine increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Aconitine CTD PMID:21277363 aconitine multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of Aconitine] which results in increased chemical synthesis of 16-O-demethylaconitine CTD PMID:21277363 acrylamide increases expression EXP 6480464 Acrylamide results in increased expression of CYP3A9 mRNA CTD PMID:15749267 actinomycin D multiple interactions ISO RGD:1348646 6480464 Dactinomycin inhibits the reaction [U 0126 results in increased expression of CYP3A5 mRNA] CTD PMID:24819614 afimoxifene decreases activity ISO RGD:1348646 6480464 afimoxifene results in decreased activity of CYP3A5 protein CTD PMID:12419016 afimoxifene increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of afimoxifene CTD PMID:29285606 afimoxifene multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of afimoxifene] which results in increased abundance of afimoxifene metabolite CTD PMID:29285606 aflatoxin B1 increases activity ISO RGD:1348646 6480464 CYP3A5 protein results in increased activity of Aflatoxin B1 CTD PMID:15454734 aflatoxin B1 decreases expression EXP 6480464 Aflatoxin B1 results in decreased expression of CYP3A9 mRNA CTD PMID:33354967 aflatoxin B1 decreases expression ISO RGD:1348646 6480464 Aflatoxin B1 results in decreased expression of CYP3A5 mRNA CTD PMID:22100608 more ... aflatoxin B1 increases expression ISO RGD:1348646 6480464 Aflatoxin B1 results in increased expression of CYP3A5 mRNA CTD PMID:21632981 , PMID:21994236 aflatoxin B1 affects expression ISO RGD:1348646 6480464 Aflatoxin B1 affects the expression of CYP3A5 protein CTD PMID:20106945 Aflatoxin G1 increases response to substance ISO RGD:1348646 6480464 CYP3A5 protein results in increased susceptibility to aflatoxin G1 CTD PMID:11189750 alfentanil multiple interactions ISO RGD:1348646 6480464 CYB5A protein promotes the reaction [CYP3A5 protein affects the metabolism of Alfentanil] more ... CTD PMID:15557344 , PMID:15731592 alfentanil affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Alfentanil CTD PMID:15557344 more ... all-trans-retinoic acid increases expression EXP 6480464 Tretinoin results in increased expression of CYP3A9 mRNA CTD PMID:24977338 alpha-tocotrienol multiple interactions ISO RGD:1348646 6480464 tocotrienol more ... CTD PMID:31102695 alpha-tocotrienol affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the susceptibility to tocotrienol, alpha CTD PMID:31102695 alprazolam increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Alprazolam CTD PMID:15903124 amiodarone affects expression EXP 6480464 Amiodarone affects the expression of CYP3A9 mRNA CTD PMID:19483382 amiodarone decreases response to substance ISO RGD:1348646 6480464 CYP3A5 protein results in decreased susceptibility to Amiodarone CTD PMID:26477383 amitriptyline increases metabolic processing ISO RGD:1348646 6480464 Amitriptyline results in increased metabolism of CYP3A5 protein CTD PMID:18359012 amlodipine affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene affects the susceptibility to Amlodipine CTD PMID:22149319 ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of CYP3A9 mRNA CTD PMID:16483693 amodiaquine increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Amodiaquine CTD PMID:31629065 amodiaquine multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine CTD PMID:31629065 antimycin A increases expression ISO RGD:1348646 6480464 Antimycin A results in increased expression of CYP3A5 mRNA CTD PMID:34642769 antirheumatic drug increases expression ISO RGD:1348646 6480464 Antirheumatic Agents results in increased expression of CYP3A5 mRNA CTD PMID:24449571 Aroclor 1254 increases expression ISO RGD:1348646 6480464 Chlorodiphenyl (54% Chlorine) results in increased expression of CYP3A5 mRNA CTD PMID:17851650 arotinoid acid multiple interactions ISO RGD:1348646 6480464 [4-(2-(5 more ... CTD PMID:34480604 arsane multiple interactions ISO RGD:1348646 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP3A5 mRNA CTD PMID:32525701 arsenic atom multiple interactions ISO RGD:1348646 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP3A5 mRNA CTD PMID:32525701 atazanavir sulfate multiple interactions ISO RGD:1348646 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 azoxystrobin increases expression ISO RGD:1348646 6480464 azoxystrobin results in increased expression of CYP3A5 mRNA CTD PMID:34642769 beclomethasone multiple interactions ISO RGD:1348646 6480464 1-aminobenzotriazole inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] more ... CTD PMID:12538830 , PMID:24555085 beclomethasone increases expression ISO RGD:1348646 6480464 Beclomethasone results in increased expression of CYP3A5 mRNA CTD PMID:12538830 more ... Benoxacor decreases expression ISO RGD:731686 6480464 benoxacor results in decreased expression of CYP3A13 mRNA CTD PMID:34850242 benzbromarone affects expression EXP 6480464 Benzbromarone affects the expression of CYP3A9 mRNA CTD PMID:19483382 benzo[a]pyrene increases expression ISO RGD:1348646 6480464 Benzo(a)pyrene results in increased expression of CYP3A5 mRNA CTD PMID:20106945 more ... benzo[a]pyrene decreases expression ISO RGD:1348646 6480464 Benzo(a)pyrene results in decreased expression of CYP3A5 mRNA CTD PMID:32234424 benzo[a]pyrene increases expression ISO RGD:731686 6480464 Benzo(a)pyrene results in increased expression of CYP3A13 mRNA, Benzo(a)pyrene results in increased expression of CYP3A13 protein CTD PMID:20127859 , PMID:34472326 benzo[a]pyrene diol epoxide I increases expression ISO RGD:1348646 6480464 7 more ... CTD PMID:19150397 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1348646 6480464 7 more ... CTD PMID:20018196 Benzo[k]fluoranthene decreases expression ISO RGD:731686 6480464 benzo(k)fluoranthene results in decreased expression of CYP3A13 mRNA CTD PMID:26377693 beta-naphthoflavone multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of CYP3A13 mRNA CTD PMID:18164116 beta-naphthoflavone decreases expression ISO RGD:1348646 6480464 beta-Naphthoflavone results in decreased expression of CYP3A5 mRNA CTD PMID:33263786 bis(2-ethylhexyl) phthalate increases expression EXP 6480464 Diethylhexyl Phthalate results in increased expression of CYP3A9 mRNA CTD PMID:19850644 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1348646 6480464 Diethylhexyl Phthalate results in decreased expression of CYP3A5 mRNA CTD PMID:31163220 bis(2-ethylhexyl) phthalate increases expression ISO RGD:731686 6480464 Diethylhexyl Phthalate results in increased expression of CYP3A13 mRNA CTD PMID:19850644 bis(2-ethylhexyl) phthalate multiple interactions ISO RGD:731686 6480464 PPARA protein promotes the reaction [Diethylhexyl Phthalate results in increased expression of CYP3A13 mRNA] CTD PMID:19850644 bisphenol A increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of bisphenol A CTD PMID:21402134 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of CYP3A5 mRNA, bisphenol A results in decreased expression of CYP3A9 mRNA CTD PMID:25181051 , PMID:34947998 bisphenol A multiple interactions ISO RGD:1348646 6480464 [bisphenol A results in increased activity of NR1I2 protein] which results in increased expression of CYP3A11 mRNA more ... CTD PMID:21402134 more ... bromobenzene decreases expression EXP 6480464 bromobenzene results in decreased expression of CYP3A9 mRNA CTD PMID:17538237 budesonide multiple interactions ISO RGD:1348646 6480464 Ketoconazole inhibits the reaction [Budesonide results in increased expression of CYP3A5 mRNA], Mifepristone inhibits the reaction [Budesonide results in increased expression of CYP3A5 mRNA] CTD PMID:12538830 , PMID:24555085 budesonide increases expression EXP 6480464 Budesonide results in increased expression of CYP3A9 mRNA CTD PMID:19562681 , PMID:20888898 budesonide increases expression ISO RGD:1348646 6480464 Budesonide results in increased expression of CYP3A5 mRNA CTD PMID:12538830 , PMID:24555085 bupivacaine multiple interactions EXP 6480464 [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA CTD PMID:22341215 buspirone increases oxidation ISO RGD:1348646 6480464 CYP3A5 protein results in increased oxidation of Buspirone CTD PMID:15640381 buspirone increases expression EXP 6480464 Buspirone results in increased expression of CYP3A9 mRNA CTD PMID:24136188 butyric acid increases expression ISO RGD:1348646 6480464 Butyric Acid results in increased expression of CYP3A5 mRNA CTD PMID:30439556 cadmium dichloride affects expression EXP 6480464 Cadmium Chloride affects the expression of CYP3A9 mRNA CTD PMID:22110744 calciol increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Cholecalciferol CTD PMID:16207822 calcitriol increases expression ISO RGD:1348646 6480464 Calcitriol results in increased expression of CYP3A5 mRNA CTD PMID:16002434 more ... calcitriol multiple interactions ISO RGD:1348646 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of CYP3A5 mRNA CTD PMID:21592394 cannabidiol decreases activity ISO RGD:1348646 6480464 Cannabidiol results in decreased activity of CYP3A5 protein CTD PMID:24667653 carbamazepine increases expression ISO RGD:1348646 6480464 Carbamazepine results in increased expression of CYP3A5 mRNA CTD PMID:12673034 carbon nanotube increases expression ISO RGD:731686 6480464 Nanotubes more ... CTD PMID:25554681 , PMID:25620056 carbosulfan increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of carbosulfan CTD PMID:20307514 carfentanil increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of carfentanil CTD PMID:33652071 carmustine multiple interactions ISO RGD:1348646 6480464 CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] CTD PMID:16087946 CGP 52608 multiple interactions ISO RGD:1348646 6480464 CGP 52608 promotes the reaction [RORA protein binds to CYP3A5 gene] CTD PMID:28238834 chenodeoxycholic acid multiple interactions ISO RGD:1348646 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... CTD PMID:33819548 CHIR 99021 multiple interactions ISO RGD:1348646 6480464 [4-(2-(5 more ... CTD PMID:34480604 chloroethene decreases expression ISO RGD:731686 6480464 Vinyl Chloride results in decreased expression of CYP3A13 mRNA CTD PMID:18579281 chlorpromazine decreases response to substance ISO RGD:1348646 6480464 CYP3A5 protein results in decreased susceptibility to Chlorpromazine CTD PMID:26477383 chlorpyrifos increases expression ISO RGD:1348646 6480464 Chlorpyrifos results in increased expression of CYP3A5 mRNA CTD PMID:16757081 , PMID:33011216 chlorpyrifos affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Chlorpyrifos CTD PMID:17079358 , PMID:17110060 chlorzoxazone affects metabolic processing EXP 6480464 CYP3A9 protein affects the metabolism of Chlorzoxazone CTD PMID:15879494 cisplatin multiple interactions ISO RGD:1348646 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of CYP3A5 mRNA, CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] CTD PMID:16087946 , PMID:27392435 cisplatin multiple interactions ISO RGD:731686 6480464 [Cisplatin co-treated with RELB mutant form co-treated with TNF protein] results in decreased expression of CYP3A13 mRNA CTD PMID:23625948 citral multiple interactions ISO RGD:1348646 6480464 [[CYP1A1 protein co-treated with CYP1B1 protein co-treated with CYP2B6 protein co-treated with CYP2E1 protein co-treated with CYP3A5 protein] results in increased metabolism of geraniol] which results in increased chemical synthesis of citral more ... CTD PMID:18824010 clobetasol increases expression ISO RGD:1348646 6480464 Clobetasol results in increased expression of CYP3A5 mRNA CTD PMID:16882163 clofibrate affects expression EXP 6480464 Clofibrate affects the expression of CYP3A9 mRNA CTD PMID:19483382 clofibrate multiple interactions ISO RGD:731686 6480464 [Clofibrate co-treated with Acetaminophen] affects the expression of CYP3A13 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CYP3A13 mRNA] CTD PMID:17585979 clofibric acid multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of CYP3A13 mRNA CTD PMID:17602206 clopidogrel affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the susceptibility to clopidogrel CTD PMID:16754899 clopidogrel multiple interactions ISO RGD:1348646 6480464 CYP3A5 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite CTD PMID:19170597 clothianidin multiple interactions ISO RGD:1348646 6480464 [clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein, [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA CTD PMID:32201337 clothianidin increases expression ISO RGD:1348646 6480464 clothianidin results in increased expression of CYP3A5 mRNA CTD PMID:32201337 clotrimazole increases expression ISO RGD:1348646 6480464 Clotrimazole results in increased expression of CYP3A5 protein CTD PMID:8632764 clozapine increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Clozapine CTD PMID:18809730 Clozapine N-oxide increases chemical synthesis ISO RGD:1348646 6480464 CYP3A5 protein results in increased chemical synthesis of clozapine N-oxide CTD PMID:18809730 cobalt dichloride decreases expression ISO RGD:1348646 6480464 cobaltous chloride results in decreased expression of CYP3A5 mRNA CTD PMID:22941251 copper atom increases expression EXP 6480464 Copper results in increased expression of CYP3A13 mRNA CTD PMID:22465980 copper(0) increases expression EXP 6480464 Copper results in increased expression of CYP3A13 mRNA CTD PMID:22465980 copper(II) sulfate increases expression ISO RGD:1348646 6480464 Copper Sulfate results in increased expression of CYP3A5 mRNA CTD PMID:19549813 cortisol increases expression ISO RGD:1348646 6480464 Hydrocortisone results in increased expression of CYP3A5 mRNA CTD PMID:23223499 cortisol multiple interactions ISO RGD:1348646 6480464 [4-(2-(5 more ... CTD PMID:34480604 Cuprizon decreases expression EXP 6480464 Cuprizone results in decreased expression of CYP3A9 mRNA CTD PMID:27523638 cyazofamid decreases expression ISO RGD:1348646 6480464 cyazofamid results in decreased expression of CYP3A5 mRNA CTD PMID:34642769 cyclophosphamide affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Cyclophosphamide CTD PMID:16087946 cyclophosphamide increases expression ISO RGD:731686 6480464 Cyclophosphamide results in increased expression of CYP3A13 mRNA CTD PMID:24819615 cyclophosphamide multiple interactions ISO RGD:1348646 6480464 CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] CTD PMID:16087946 cyclophosphamide affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the susceptibility to Cyclophosphamide CTD PMID:16087946 cyclosporin A increases expression ISO RGD:1348646 6480464 Cyclosporine results in increased expression of CYP3A5 mRNA CTD PMID:12673034 cyclosporin A multiple interactions ISO RGD:1348646 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 cyclosporin A decreases expression ISO RGD:1348646 6480464 Cyclosporine results in decreased expression of CYP3A5 mRNA CTD PMID:20106945 , PMID:25562108 cyclosporin A affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Cyclosporine, CYP3A5 protein polymorphism affects the metabolism of Cyclosporine CTD PMID:15450954 more ... cypermethrin increases expression ISO RGD:731686 6480464 cypermethrin results in increased expression of CYP3A13 mRNA CTD PMID:31659573 cypermethrin multiple interactions ISO RGD:731686 6480464 Sodium Selenite inhibits the reaction [cypermethrin results in increased expression of CYP3A13 mRNA] CTD PMID:31659573 cyproconazole increases expression EXP 6480464 cyproconazole results in increased expression of CYP3A9 protein CTD PMID:33150952 dabrafenib decreases activity ISO RGD:1348646 6480464 dabrafenib results in decreased activity of CYP3A5 protein CTD PMID:34780725 decabromodiphenyl ether increases expression EXP 6480464 decabromobiphenyl ether results in increased expression of CYP3A9 mRNA CTD PMID:32679240 Dechloroethylcyclophosphamide affects chemical synthesis ISO RGD:1348646 6480464 CYP3A5 protein affects the chemical synthesis of dechloroethylcyclophosphamide CTD PMID:15875221 deguelin affects expression ISO RGD:1348646 6480464 deguelin affects the expression of CYP3A5 mRNA CTD PMID:34642769 dehydroepiandrosterone increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Dehydroepiandrosterone CTD PMID:15845858 delta-tocotrienol multiple interactions ISO RGD:1348646 6480464 tocotrienol more ... CTD PMID:31102695 delta-tocotrienol affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the susceptibility to tocotrienol, delta CTD PMID:31102695 deoxycholic acid multiple interactions ISO RGD:1348646 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... CTD PMID:33819548 dexamethasone increases expression ISO RGD:731686 6480464 Dexamethasone results in increased expression of CYP3A13 mRNA CTD PMID:14570766 , PMID:31678242 dexamethasone increases expression EXP 6480464 Dexamethasone results in increased expression of CYP3A9 mRNA CTD PMID:19562681 , PMID:20888898 dexamethasone increases expression ISO RGD:1348646 6480464 Dexamethasone results in increased expression of CYP3A5 mRNA CTD PMID:10696073 more ... dexamethasone multiple interactions ISO RGD:1348646 6480464 Mifepristone inhibits the reaction [Dexamethasone results in increased expression of CYP3A5 mRNA], NR3C1 protein affects the reaction [Dexamethasone results in increased expression of CYP3A5 mRNA] CTD PMID:12538830 dexamethasone multiple interactions EXP 6480464 [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA CTD PMID:22341215 dexamethasone decreases expression EXP 6480464 Dexamethasone results in decreased expression of CYP3A9 mRNA CTD PMID:15102944 dextran sulfate multiple interactions ISO RGD:731686 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA CTD PMID:29950665 dextromethorphan affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Dextromethorphan CTD PMID:15988119 dextromethorphan increases oxidation ISO RGD:1348646 6480464 CYP3A5 protein results in increased oxidation of Dextromethorphan CTD PMID:15383492 dextromethorphan decreases methylation ISO RGD:1348646 6480464 CYP3A5 protein results in decreased methylation of Dextromethorphan CTD PMID:15383492 dextrorphan affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Dextrorphan CTD PMID:15988119 diazinon increases expression ISO RGD:1348646 6480464 Diazinon results in increased expression of CYP3A5 mRNA CTD PMID:16757081 diclofenac increases expression ISO RGD:731686 6480464 Diclofenac results in increased expression of CYP3A13 mRNA CTD PMID:26934552 diclofenac decreases activity ISO RGD:731686 6480464 Diclofenac metabolite results in decreased activity of CYP3A13 protein CTD PMID:28960974 dicrotophos decreases expression ISO RGD:1348646 6480464 dicrotophos results in decreased expression of CYP3A5 mRNA CTD PMID:28302478 diltiazem decreases methylation ISO RGD:1348646 6480464 CYP3A5 protein results in decreased methylation of Diltiazem CTD PMID:15499178 diltiazem affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Diltiazem, CYP3A5 protein polymorphism affects the metabolism of Diltiazem CTD PMID:16024008 dimethyl sulfoxide affects expression ISO RGD:1348646 6480464 Dimethyl Sulfoxide affects the expression of CYP3A5 mRNA CTD PMID:12843640 diosmetin multiple interactions ISO RGD:1348646 6480464 diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] CTD PMID:18191104 disodium selenite multiple interactions ISO RGD:731686 6480464 Sodium Selenite inhibits the reaction [cypermethrin results in increased expression of CYP3A13 mRNA] CTD PMID:31659573 Droloxifene decreases activity ISO RGD:1348646 6480464 droloxifene results in decreased activity of CYP3A5 protein CTD PMID:12419016 dronedarone increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of dronedarone CTD PMID:29616291 dronedarone multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of Dronedarone] which results in increased abundance of N-desbutyldronedarone more ... CTD PMID:29616291 dronedarone decreases response to substance ISO RGD:1348646 6480464 CYP3A5 protein results in decreased susceptibility to dronedarone CTD PMID:29616291 elemental selenium decreases expression ISO RGD:1348646 6480464 Selenium results in decreased expression of CYP3A5 mRNA CTD PMID:19244175 emodin increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Emodin CTD PMID:30672276 endosulfan affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Endosulfan CTD PMID:16581944 endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of CYP3A9 mRNA CTD PMID:29391264 enilconazole multiple interactions ISO RGD:1348646 6480464 [clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein, [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein CTD PMID:32201337 enilconazole increases expression ISO RGD:1348646 6480464 enilconazole results in increased expression of CYP3A5 mRNA, enilconazole results in increased expression of CYP3A5 protein CTD PMID:32201337 eplerenone increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Eplerenone CTD PMID:31408697 eplerenone increases abundance ISO RGD:1348646 6480464 CYP3A5 protein results in increased abundance of Eplerenone metabolite CTD PMID:31408697 erythromycin A decreases methylation ISO RGD:1348646 6480464 CYP3A5 protein results in decreased methylation of Erythromycin CTD PMID:15383492 erythromycin estolate increases expression EXP 6480464 Erythromycin Estolate results in increased expression of CYP3A9 mRNA CTD PMID:24412560 ethanol increases expression ISO RGD:731686 6480464 Ethanol results in increased expression of CYP3A13 mRNA CTD PMID:19167417 etoposide affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the susceptibility to Etoposide CTD PMID:12969965 etoposide decreases methylation ISO RGD:1348646 6480464 CYP3A5 protein results in decreased methylation of Etoposide CTD PMID:8114683 fenofibrate multiple interactions EXP 6480464 [Fenofibrate co-treated with Diethylnitrosamine] results in decreased expression of CYP3A13 mRNA CTD PMID:18253720 fenpyroximate increases expression ISO RGD:1348646 6480464 fenpyroximate results in increased expression of CYP3A5 mRNA CTD PMID:34642769 fenthion affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Fenthion CTD PMID:17110060 fimasartan increases oxidation ISO RGD:1348646 6480464 CYP3A5 protein results in increased oxidation of fimasartan CTD PMID:29596975 fimasartan increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of fimasartan CTD PMID:29596975 fipronil increases expression EXP 6480464 fipronil results in increased expression of CYP3A9 mRNA CTD PMID:23962444 fipronil multiple interactions ISO RGD:1348646 6480464 [fipronil co-treated with DEET] results in increased expression of CYP3A5 mRNA CTD PMID:27091632 fipronil increases expression ISO RGD:1348646 6480464 fipronil results in increased expression of CYP3A5 mRNA CTD PMID:17084830 , PMID:27091632 flavonol increases expression ISO RGD:1348646 6480464 3-hydroxyflavone results in increased expression of CYP3A5 mRNA CTD PMID:26238175 fluconazole increases expression EXP 6480464 Fluconazole results in increased expression of CYP3A13 mRNA CTD PMID:16643972 flunisolide multiple interactions ISO RGD:1348646 6480464 Ketoconazole inhibits the reaction [flunisolide results in increased expression of CYP3A5 mRNA] CTD PMID:24555085 flunisolide increases expression ISO RGD:1348646 6480464 flunisolide results in increased expression of CYP3A5 mRNA CTD PMID:24555085 flunitrazepam increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Flunitrazepam CTD PMID:15383492 fluoxetine multiple interactions ISO RGD:1348646 6480464 Fluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] CTD PMID:12584149 fluticasone affects response to substance ISO RGD:1348646 6480464 CYP3A5 protein affects the susceptibility to Fluticasone CTD PMID:20707410 fluticasone decreases activity ISO RGD:1348646 6480464 Fluticasone results in decreased activity of CYP3A5 protein CTD PMID:20707410 fluticasone multiple interactions ISO RGD:1348646 6480464 Ketoconazole inhibits the reaction [Fluticasone results in increased expression of CYP3A5 mRNA] CTD PMID:24555085 fluticasone increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Fluticasone CTD PMID:20707410 fluticasone increases expression ISO RGD:1348646 6480464 Fluticasone results in increased expression of CYP3A5 mRNA CTD PMID:24555085 fluvoxamine multiple interactions ISO RGD:1348646 6480464 Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] CTD PMID:12584149 folic acid decreases expression ISO RGD:731686 6480464 Folic Acid results in decreased expression of CYP3A13 mRNA CTD PMID:25629700 fumonisin B1 decreases expression ISO RGD:731686 6480464 fumonisin B1 results in decreased expression of CYP3A13 mRNA CTD PMID:16221962 gallocatechin multiple interactions ISO RGD:731686 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA CTD PMID:25663641 gefitinib affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of gefitinib CTD PMID:15788367 Gelsemine increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of gelsemine CTD PMID:34627953 genistein multiple interactions EXP 6480464 [Genistein co-treated with Methoxychlor] results in increased expression of CYP3A9 mRNA CTD PMID:21782745 genistein decreases expression ISO RGD:731686 6480464 Genistein results in decreased expression of CYP3A13 mRNA CTD PMID:32186404 geranial multiple interactions ISO RGD:1348646 6480464 [[CYP1A1 protein co-treated with CYP1B1 protein co-treated with CYP2B6 protein co-treated with CYP2E1 protein co-treated with CYP3A5 protein] results in increased metabolism of geraniol] which results in increased chemical synthesis of citral more ... CTD PMID:18824010 geraniol increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of geraniol CTD PMID:18824010 geraniol multiple interactions ISO RGD:1348646 6480464 [[CYP1A1 protein co-treated with CYP1B1 protein co-treated with CYP2B6 protein co-treated with CYP2E1 protein co-treated with CYP3A5 protein] results in increased metabolism of geraniol] which results in increased chemical synthesis of citral more ... CTD PMID:18824010 glutathione multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 2'-(glutathion-S-yl)-deschlorodiclofenac more ... CTD PMID:24246759 , PMID:26302866 glycochenodeoxycholic acid multiple interactions ISO RGD:1348646 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... CTD PMID:33819548 glycocholic acid multiple interactions ISO RGD:1348646 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... CTD PMID:33819548 glycodeoxycholic acid multiple interactions ISO RGD:1348646 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA more ... CTD PMID:33819548 haloperidol multiple interactions ISO RGD:1348646 6480464 CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol more ... CTD PMID:12584149 helenalin decreases activity ISO RGD:1348646 6480464 helenalin results in decreased activity of CYP3A5 protein CTD PMID:34989853 helenalin increases oxidation ISO RGD:1348646 6480464 CYP3A5 protein results in increased oxidation of helenalin CTD PMID:34989853 Heliotrine decreases expression ISO RGD:1348646 6480464 heliotrine results in decreased expression of CYP3A5 mRNA CTD PMID:26100227 Hexachloro-1,3-butadiene increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of hexachlorobutadiene CTD PMID:8555406 hydroquinone multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of bisphenol A] which results in increased chemical synthesis of hydroquinone CTD PMID:21402134 Hypaconitine increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of hypaconitine CTD PMID:21550385 hyperforin increases expression ISO RGD:1348646 6480464 hyperforin results in increased expression of CYP3A5 mRNA CTD PMID:24259679 ifosfamide affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Ifosfamide CTD PMID:15875221 ifosfamide decreases ethylation ISO RGD:1348646 6480464 CYP3A5 protein results in decreased ethylation of Ifosfamide CTD PMID:15821045 indole-3-methanol affects expression EXP 6480464 indole-3-carbinol affects the expression of CYP3A9 mRNA CTD PMID:21396975 indometacin increases expression EXP 6480464 Indomethacin results in increased expression of CYP3A9 mRNA CTD PMID:18299717 irinotecan multiple interactions ISO RGD:1348646 6480464 [selenomethylselenocysteine co-treated with Irinotecan] results in increased expression of CYP3A5 CTD PMID:15897249 ketoconazole multiple interactions ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the reaction [Ketoconazole results in decreased metabolism of Tacrolimus] more ... CTD PMID:15731592 more ... ketoconazole affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the susceptibility to Ketoconazole CTD PMID:31102695 ketoconazole decreases activity ISO RGD:1348646 6480464 Ketoconazole results in decreased activity of CYP3A5 protein CTD PMID:15557344 , PMID:26302866 L-ascorbic acid multiple interactions ISO RGD:1348646 6480464 [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA CTD PMID:34480604 L-ascorbic acid 2-phosphate multiple interactions ISO RGD:1348646 6480464 [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA CTD PMID:34480604 L-ethionine affects expression EXP 6480464 Ethionine affects the expression of CYP3A9 mRNA CTD PMID:19483382 lansoprazole multiple interactions ISO RGD:1348646 6480464 CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole] CTD PMID:17377957 lapatinib increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of lapatinib CTD PMID:26958860 lapatinib multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein CTD PMID:26958860 Lasiocarpine increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of lasiocarpine CTD PMID:31103741 lead diacetate increases expression EXP 6480464 lead acetate results in increased expression of CYP3A9 mRNA CTD PMID:22641619 lidocaine decreases methylation ISO RGD:1348646 6480464 CYP3A5 protein results in decreased methylation of Lidocaine CTD PMID:15383492 lipopolysaccharide increases expression ISO RGD:1348646 6480464 Lipopolysaccharides results in increased expression of CYP3A5 mRNA CTD PMID:35811015 lipopolysaccharide multiple interactions ISO RGD:1348646 6480464 [S-(1 more ... CTD PMID:35811015 lithocholic acid increases expression EXP 6480464 Lithocholic Acid results in increased expression of CYP3A9 mRNA CTD PMID:20888898 lithocholic acid increases oxidation ISO RGD:1348646 6480464 CYP3A5 protein results in increased oxidation of Lithocholic Acid CTD PMID:31102695 lithocholic acid multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased oxidation of Lithocholic Acid] which results in increased chemical synthesis of 3-ketocholanoic acid more ... CTD PMID:14570758 , PMID:31102695 luteolin multiple interactions ISO RGD:1348646 6480464 Luteolin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] CTD PMID:18191104 malathion affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Malathion CTD PMID:17110060 Meclizine multiple interactions ISO RGD:1348646 6480464 Meclizine inhibits the reaction [[Phenobarbital results in increased activity of NR1I3 protein] which results in increased expression of CYP3A11 mRNA] more ... CTD PMID:15272053 , PMID:26239802 methoxychlor decreases methylation EXP 6480464 CYP3A5 protein results in decreased methylation of Methoxychlor CTD PMID:12433799 methoxychlor increases expression EXP 6480464 Methoxychlor results in increased expression of CYP3A9 mRNA CTD PMID:21782745 methoxychlor multiple interactions EXP 6480464 [Genistein co-treated with Methoxychlor] results in increased expression of CYP3A9 mRNA CTD PMID:21782745 midazolam increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Midazolam CTD PMID:26958860 midazolam multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam more ... CTD PMID:19557931 , PMID:34189909 midazolam increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Midazolam CTD PMID:15383492 more ... midazolam affects metabolic processing EXP 6480464 CYP3A5 protein affects the metabolism of Midazolam CTD PMID:15801540 midazolam affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the metabolism of Midazolam, CYP3A5 protein affects the metabolism of Midazolam CTD PMID:15801540 more ... mifepristone multiple interactions ISO RGD:1348646 6480464 Mifepristone inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] more ... CTD PMID:12538830 monosodium L-glutamate decreases expression EXP 6480464 Sodium Glutamate results in decreased expression of CYP3A9 mRNA CTD PMID:20928830 monosodium L-glutamate multiple interactions ISO RGD:731686 6480464 [Sodium Glutamate co-treated with gallocatechol co-treated with Catechin co-treated with epigallocatechin gallate co-treated with epicatechin gallate co-treated with gallocatechol co-treated with gallocatechin gallate] affects the expression of CYP3A13 mRNA, [Sodium Glutamate co-treated with Tea] affects the expression of CYP3A13 mRNA CTD PMID:25663641 mycophenolic acid increases methylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased methylation of Mycophenolic Acid CTD PMID:15570183 N,N-diethyl-m-toluamide increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of DEET CTD PMID:11854147 N,N-diethyl-m-toluamide multiple interactions ISO RGD:1348646 6480464 [fipronil co-treated with DEET] results in increased expression of CYP3A5 mRNA CTD PMID:27091632 N,N-diethyl-m-toluamide increases expression ISO RGD:1348646 6480464 DEET results in increased expression of CYP3A5 mRNA CTD PMID:27091632 N-desmethylclozapine increases chemical synthesis ISO RGD:1348646 6480464 CYP3A5 protein results in increased chemical synthesis of norclozapine CTD PMID:18809730 N-Desmethyltamoxifen decreases activity ISO RGD:1348646 6480464 N-desmethyltamoxifen results in decreased activity of CYP3A5 protein CTD PMID:12419016 N-Desmethyltamoxifen multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of N-desmethyltamoxifen] which results in increased abundance of 1-(4-hydroxyphenyl)-1, 2-diphenyl-1-butene CTD PMID:29285606 N-Desmethyltamoxifen increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of N-desmethyltamoxifen CTD PMID:29285606 N-methyl-4-phenylpyridinium increases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in increased expression of CYP3A9 mRNA CTD PMID:28801915 N-nitrosodiethylamine increases expression ISO RGD:731686 6480464 Diethylnitrosamine results in increased expression of CYP3A13 mRNA CTD PMID:17942915 N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of CYP3A13 mRNA more ... CTD PMID:17602206 more ... N-nitrosodiethylamine decreases expression EXP 6480464 Diethylnitrosamine results in decreased expression of CYP3A13 mRNA CTD PMID:19638242 N-nitrosodiethylamine multiple interactions ISO RGD:731686 6480464 MET protein inhibits the reaction [Diethylnitrosamine results in increased expression of CYP3A13 mRNA] CTD PMID:17942915 N-nitrosodimethylamine decreases expression EXP 6480464 Dimethylnitrosamine results in decreased expression of CYP3A9 mRNA CTD PMID:25380136 N-nitrosodimethylamine increases expression EXP 6480464 Dimethylnitrosamine results in increased expression of CYP3A13 mRNA CTD PMID:17072980 N-Vinyl-2-pyrrolidone multiple interactions EXP 6480464 [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CYP3A9 mRNA CTD PMID:22037397 naphthalene increases expression ISO RGD:1348646 6480464 naphthalene results in increased expression of CYP3A5 mRNA CTD PMID:20500019 nefazodone multiple interactions ISO RGD:1348646 6480464 nefazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] CTD PMID:12584149 nefazodone increases expression EXP 6480464 nefazodone results in increased expression of CYP3A9 mRNA CTD PMID:24136188 nelfinavir decreases activity ISO RGD:1348646 6480464 Nelfinavir results in decreased activity of CYP3A5 protein CTD PMID:15523003 nevirapine increases expression EXP 6480464 Nevirapine results in increased expression of CYP3A9 mRNA CTD PMID:23947594 nickel atom decreases expression ISO RGD:1348646 6480464 Nickel results in decreased expression of CYP3A5 mRNA CTD PMID:24768652 , PMID:25583101 nimesulide increases expression EXP 6480464 nimesulide results in increased expression of CYP3A9 mRNA CTD PMID:24136188 Norfluoxetine multiple interactions ISO RGD:1348646 6480464 norfluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] CTD PMID:12584149 nortriptyline increases metabolic processing ISO RGD:1348646 6480464 Nortriptyline results in increased metabolism of CYP3A5 protein CTD PMID:18359012 norverapamil decreases activity ISO RGD:1348646 6480464 norverapamil results in decreased activity of CYP3A5 protein CTD PMID:15689501 obeticholic acid decreases expression ISO RGD:1348646 6480464 obeticholic acid results in decreased expression of CYP3A5 mRNA CTD PMID:27939613 ochratoxin A increases response to substance ISO RGD:1348646 6480464 CYP3A5 protein results in increased susceptibility to ochratoxin A CTD PMID:11189750 ochratoxin A decreases expression ISO RGD:1348646 6480464 ochratoxin A results in decreased expression of CYP3A5 mRNA CTD PMID:26505656 ochratoxin A increases expression ISO RGD:1348646 6480464 ochratoxin A results in increased expression of CYP3A5 mRNA CTD PMID:21834667 okadaic acid multiple interactions ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of and results in increased hydroxylation of and results in decreased susceptibility to Okadaic Acid CTD PMID:26374342 omeprazole affects expression EXP 6480464 Omeprazole affects the expression of CYP3A9 mRNA CTD PMID:19483382 omeprazole increases expression ISO RGD:1348646 6480464 Omeprazole results in increased expression of CYP3A5 mRNA CTD PMID:19118567 ozone multiple interactions ISO RGD:731686 6480464 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of CYP3A13 mRNA, [Air Pollutants results in increased abundance of Ozone] which results in increased expression of CYP3A13 mRNA CTD PMID:34911549 paracetamol multiple interactions ISO RGD:731686 6480464 [Clofibrate co-treated with Acetaminophen] affects the expression of CYP3A13 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CYP3A13 mRNA] CTD PMID:17585979 paracetamol multiple interactions ISO RGD:1348646 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 paracetamol decreases expression ISO RGD:1348646 6480464 Acetaminophen results in decreased expression of CYP3A5 mRNA CTD PMID:29067470 paracetamol increases expression ISO RGD:1348646 6480464 Acetaminophen results in increased expression of CYP3A5 mRNA CTD PMID:26497421 paracetamol affects expression EXP 6480464 Acetaminophen affects the expression of CYP3A13 mRNA CTD PMID:17366322 paracetamol affects expression ISO RGD:731686 6480464 Acetaminophen affects the expression of CYP3A13 mRNA CTD PMID:17562736 paraoxon multiple interactions ISO RGD:1348646 6480464 Paraoxon inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] CTD PMID:24555085 parathion affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Parathion CTD PMID:12669189 more ... PD 0325901 increases expression ISO RGD:1348646 6480464 mirdametinib results in increased expression of CYP3A5 mRNA CTD PMID:24819614 perfluorohexanesulfonic acid increases expression ISO RGD:1348646 6480464 perfluorohexanesulfonic acid results in increased expression of CYP3A5 mRNA CTD PMID:23567314 perfluorooctane-1-sulfonic acid increases expression ISO RGD:731686 6480464 perfluorooctane sulfonic acid results in increased expression of CYP3A13 mRNA CTD PMID:20936131 perfluorooctane-1-sulfonic acid decreases expression ISO RGD:1348646 6480464 perfluorooctane sulfonic acid results in decreased expression of CYP3A5 mRNA CTD PMID:27153767 perfluorooctanoic acid increases expression ISO RGD:731686 6480464 perfluorooctanoic acid results in increased expression of CYP3A13 mRNA CTD PMID:25949234 perfluorooctanoic acid affects expression ISO RGD:731686 6480464 perfluorooctanoic acid affects the expression of CYP3A13 mRNA CTD PMID:18281256 permethrin increases expression ISO RGD:1348646 6480464 Permethrin results in increased expression of CYP3A5 mRNA CTD PMID:19326768 phencyclidine affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Phencyclidine CTD PMID:16782764 phenethyl isothiocyanate decreases expression ISO RGD:1348646 6480464 phenethyl isothiocyanate results in decreased expression of CYP3A5 mRNA CTD PMID:20442190 phenobarbital increases expression ISO RGD:1348646 6480464 Phenobarbital results in increased expression of CYP3A11 protein, Phenobarbital results in increased expression of CYP3A5 mRNA CTD PMID:10696073 more ... phenobarbital multiple interactions ISO RGD:1348646 6480464 [Phenobarbital results in increased activity of NR1I3 protein] which results in increased expression of CYP3A11 mRNA, Meclizine inhibits the reaction [[Phenobarbital results in increased activity of NR1I3 protein] which results in increased expression of CYP3A11 mRNA] CTD PMID:15272053 phenobarbital affects expression ISO RGD:731686 6480464 Phenobarbital affects the expression of CYP3A13 mRNA CTD PMID:23091169 phenobarbital increases expression ISO RGD:731686 6480464 Phenobarbital results in increased expression of CYP3A13 mRNA CTD PMID:19270015 , PMID:19850644 phenobarbital increases expression EXP 6480464 Phenobarbital results in increased expression of CYP3A9 mRNA CTD PMID:19162173 more ... phenobarbital affects expression ISO RGD:1348646 6480464 Phenobarbital affects the expression of CYP3A5 mRNA CTD PMID:19159669 phenytoin increases expression ISO RGD:731686 6480464 Phenytoin results in increased expression of CYP3A13 mRNA CTD PMID:19903449 phenytoin increases expression ISO RGD:1348646 6480464 Phenytoin results in increased expression of CYP3A5 mRNA CTD PMID:12673034 phlorizin increases expression ISO RGD:731686 6480464 Phlorhizin results in increased expression of CYP3A7 mRNA CTD PMID:22538082 phlorizin decreases expression ISO RGD:731686 6480464 Phlorhizin results in decreased expression of CYP3A7 mRNA CTD PMID:22538082 physostigmine multiple interactions ISO RGD:1348646 6480464 Physostigmine inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA] CTD PMID:24555085 picoxystrobin affects expression ISO RGD:1348646 6480464 picoxystrobin affects the expression of CYP3A5 mRNA CTD PMID:34642769 pirinixic acid multiple interactions ISO RGD:1348646 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of CYP3A5 mRNA CTD PMID:19710929 pirinixic acid increases expression ISO RGD:731686 6480464 pirinixic acid results in increased expression of CYP3A13 mRNA CTD PMID:18445702 pirinixic acid decreases expression ISO RGD:731686 6480464 pirinixic acid results in decreased expression of CYP3A13 mRNA CTD PMID:19850644 pirinixic acid multiple interactions ISO RGD:731686 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CYP3A13 mRNA CTD PMID:19710929 pirinixic acid decreases expression EXP 6480464 pirinixic acid results in decreased expression of CYP3A9 mRNA CTD PMID:19162173 more ... pirinixic acid affects expression EXP 6480464 pirinixic acid affects the expression of CYP3A9 mRNA CTD PMID:19483382 pregnenolone 16alpha-carbonitrile increases expression EXP 6480464 Pregnenolone Carbonitrile results in increased expression of CYP3A9 mRNA CTD PMID:15596064 more ... pregnenolone 16alpha-carbonitrile increases expression ISO RGD:731686 6480464 Pregnenolone Carbonitrile results in increased expression of CYP3A13 mRNA CTD PMID:28903501 pregnenolone 16alpha-carbonitrile increases expression ISO RGD:1348646 6480464 Pregnenolone Carbonitrile results in increased expression of CYP3A11 mRNA CTD PMID:26883953 pregnenolone 16alpha-carbonitrile multiple interactions ISO RGD:1348646 6480464 trichostatin A inhibits the reaction [Pregnenolone Carbonitrile results in increased expression of CYP3A11 mRNA] CTD PMID:26883953 prochloraz increases expression EXP 6480464 prochloraz results in increased expression of CYP3A9 protein CTD PMID:33150952 progesterone increases expression ISO RGD:1348646 6480464 Progesterone results in increased expression of CYP3A5 mRNA CTD PMID:22837389 pyrazinecarboxamide decreases expression EXP 6480464 Pyrazinamide results in decreased expression of CYP3A9 mRNA CTD PMID:22431067 quercetin increases expression ISO RGD:1348646 6480464 Quercetin results in increased expression of CYP3A5 mRNA CTD PMID:26238175 quercetin affects expression ISO RGD:731686 6480464 Quercetin affects the expression of CYP3A13 mRNA CTD PMID:19270413 quercetin decreases expression ISO RGD:1348646 6480464 Quercetin results in decreased expression of CYP3A5 mRNA CTD PMID:21632981 quinacrine increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Quinacrine CTD PMID:16581945 rabeprazole multiple interactions ISO RGD:1348646 6480464 CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole] CTD PMID:17377957 reactive oxygen species multiple interactions ISO RGD:1348646 6480464 CYP3A5 protein promotes the reaction [tetrandrine results in increased abundance of Reactive Oxygen Species] CTD PMID:26302866 Rebamipide increases expression EXP 6480464 rebamipide results in increased expression of CYP3A9 mRNA CTD PMID:18299717 reserpine increases expression ISO RGD:1348646 6480464 Reserpine results in increased expression of CYP3A5 protein CTD PMID:8632764 riddelliine increases expression EXP 6480464 riddelliine results in increased expression of CYP3A9 mRNA CTD PMID:18047727 rifampicin increases expression ISO RGD:1348646 6480464 Rifampin results in increased expression of CYP3A5 mRNA CTD PMID:12040753 more ... rifaximin multiple interactions ISO RGD:1348646 6480464 [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA CTD PMID:22790967 risperidone affects abundance ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the abundance of Risperidone, CYP3A5 protein affects the abundance of Risperidone CTD PMID:20332423 risperidone increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Risperidone CTD PMID:18708991 ritonavir decreases activity ISO RGD:1348646 6480464 Ritonavir results in decreased activity of CYP3A5 protein CTD PMID:15523003 rivaroxaban increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Rivaroxaban CTD PMID:34189909 rivaroxaban multiple interactions ISO RGD:1348646 6480464 erdafitinib inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Rivaroxaban] CTD PMID:34189909 romidepsin affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of romidepsin CTD PMID:15635176 rotenone increases expression ISO RGD:1348646 6480464 Rotenone results in increased expression of CYP3A5 mRNA CTD PMID:34642769 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:1348646 6480464 [S-(1 more ... CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:1348646 6480464 [LDN 193189 co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with EGF protein co-treated with FGF2 protein] results in increased expression of CYP3A5 mRNA CTD PMID:34480604 Se-methyl-L-selenocysteine multiple interactions ISO RGD:1348646 6480464 [selenomethylselenocysteine co-treated with irinotecan] results in increased expression of CYP3A5 CTD PMID:15897249 Se-methylselenocysteine multiple interactions ISO RGD:1348646 6480464 [selenomethylselenocysteine co-treated with irinotecan] results in increased expression of CYP3A5 CTD PMID:15897249 selenium atom decreases expression ISO RGD:1348646 6480464 Selenium results in decreased expression of CYP3A5 mRNA CTD PMID:19244175 senecionine decreases expression ISO RGD:1348646 6480464 senecionine results in decreased expression of CYP3A5 mRNA CTD PMID:26100227 Senkirkine decreases expression ISO RGD:1348646 6480464 senkirkine results in decreased expression of CYP3A5 mRNA CTD PMID:26100227 silicon dioxide decreases expression ISO RGD:1348646 6480464 Silicon Dioxide analog results in decreased expression of CYP3A5 mRNA CTD PMID:25895662 silicon dioxide increases expression ISO RGD:1348646 6480464 Silicon Dioxide analog results in increased expression of CYP3A5 mRNA CTD PMID:23806026 simvastatin affects response to substance ISO RGD:1348646 6480464 CYP3A5 polymorphism affects the susceptibility to Simvastatin CTD PMID:17192506 sodium arsenate multiple interactions ISO RGD:1348646 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of CYP3A5 mRNA CTD PMID:32525701 sodium arsenite decreases expression ISO RGD:731686 6480464 sodium arsenite results in decreased expression of CYP3A13 mRNA CTD PMID:11353140 sodium arsenite decreases expression ISO RGD:1348646 6480464 sodium arsenite results in decreased expression of CYP3A5 mRNA CTD PMID:29301061 sodium dichromate decreases expression EXP 6480464 sodium bichromate results in decreased expression of CYP3A9 mRNA CTD PMID:25993096 sorafenib affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein polymorphism affects the metabolism of Sorafenib CTD PMID:35099304 sulfaphenazole multiple interactions ISO RGD:1348646 6480464 Sulfaphenazole inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Testosterone] CTD PMID:31102695 tacrolimus hydrate multiple interactions ISO RGD:1348646 6480464 CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole] more ... CTD PMID:17377957 , PMID:19384264 tacrolimus hydrate decreases methylation ISO RGD:1348646 6480464 CYP3A5 protein results in decreased methylation of Tacrolimus CTD PMID:15951320 tacrolimus hydrate affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the metabolism of Tacrolimus more ... CTD PMID:15502717 more ... tacrolimus hydrate affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene affects the susceptibility to Tacrolimus CTD PMID:15723604 tamarixetin increases expression ISO RGD:1348646 6480464 tamarixetin results in increased expression of CYP3A5 mRNA CTD PMID:26238175 tamoxifen decreases expression ISO RGD:731686 6480464 Tamoxifen results in decreased expression of CYP3A13 mRNA CTD PMID:25123088 tamoxifen increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Tamoxifen CTD PMID:29285606 tamoxifen multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased metabolism of Tamoxifen] which results in increased abundance of 1-(4-hydroxyphenyl)-1, 2-diphenyl-1-butene CTD PMID:29285606 tamoxifen decreases activity ISO RGD:1348646 6480464 Tamoxifen results in decreased activity of CYP3A5 protein CTD PMID:12419016 tamoxifen affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Tamoxifen, CYP3A5 protein polymorphism affects the metabolism of Tamoxifen CTD PMID:15596297 tanespimycin affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of tanespimycin CTD PMID:15718306 tartrazine multiple interactions ISO RGD:1348646 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 tebufenpyrad increases expression ISO RGD:1348646 6480464 4-chloro-N-((4-(1, 1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide results in increased expression of CYP3A5 mRNA CTD PMID:34642769 teniposide decreases methylation ISO RGD:1348646 6480464 CYP3A5 protein results in decreased methylation of Teniposide CTD PMID:8114683 Terfenadine affects metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein affects the metabolism of Terfenadine CTD PMID:15383492 testosterone increases expression ISO RGD:1348646 6480464 Testosterone results in increased expression of CYP3A5 mRNA CTD PMID:21592394 testosterone multiple interactions EXP 6480464 [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of CYP3A9 mRNA CTD PMID:32741896 testosterone decreases expression ISO RGD:1348646 6480464 Testosterone results in decreased expression of CYP3A5 mRNA CTD PMID:33359661 testosterone increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Testosterone CTD PMID:15383492 more ... testosterone multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone more ... CTD PMID:21592394 more ... testosterone affects metabolic processing EXP 6480464 CYP3A9 protein affects the metabolism of Testosterone CTD PMID:15879494 tetrachloroethene increases expression ISO RGD:731686 6480464 Tetrachloroethylene results in increased expression of CYP3A13 mRNA CTD PMID:28973375 tetrachloromethane increases expression ISO RGD:731686 6480464 Carbon Tetrachloride results in increased expression of CYP3A13 mRNA CTD PMID:27339419 , PMID:31919559 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of CYP3A9 mRNA CTD PMID:31150632 tetrodotoxin multiple interactions EXP 6480464 [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA CTD PMID:22341215 thalidomide multiple interactions ISO RGD:1348646 6480464 [CYP3A5 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide CTD PMID:20443640 thalidomide increases expression ISO RGD:1348646 6480464 Thalidomide results in increased expression of CYP3A5 mRNA CTD PMID:28496040 thalidomide increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Thalidomide CTD PMID:28745489 thalidomide increases hydroxylation ISO RGD:1348646 6480464 CYP3A5 protein results in increased hydroxylation of Thalidomide CTD PMID:20443640 thiacloprid increases expression ISO RGD:1348646 6480464 thiacloprid results in increased expression of CYP3A5 mRNA CTD PMID:32201337 thiacloprid multiple interactions ISO RGD:1348646 6480464 [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein, [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA CTD PMID:32201337 thioacetamide affects expression EXP 6480464 Thioacetamide affects the expression of CYP3A9 mRNA CTD PMID:19483382 thioacetamide multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of CYP3A13 mRNA CTD PMID:28943392 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of CYP3A9 mRNA CTD PMID:23411599 , PMID:34492290 Thiotepa affects export ISO RGD:1348646 6480464 CYP3A5 gene SNP affects the export of Thiotepa CTD PMID:19076156 Thiotepa affects response to substance ISO RGD:1348646 6480464 CYP3A5 protein affects the susceptibility to Thiotepa CTD PMID:19076156 ticlopidine multiple interactions ISO RGD:1348646 6480464 CYP3A5 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite CTD PMID:19170597 titanium dioxide multiple interactions ISO RGD:731686 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA CTD PMID:29950665 trabectedin decreases expression EXP 6480464 trabectedin results in decreased expression of CYP3A13 mRNA CTD PMID:12154027 trazodone multiple interactions ISO RGD:1348646 6480464 Trazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] CTD PMID:12584149 triadimefon increases expression ISO RGD:731686 6480464 triadimefon results in increased expression of CYP3A13 mRNA CTD PMID:19010342 triamcinolone acetonide increases expression ISO RGD:1348646 6480464 Triamcinolone Acetonide results in increased expression of CYP3A5 mRNA CTD PMID:24555085 triamcinolone acetonide multiple interactions ISO RGD:1348646 6480464 Ketoconazole inhibits the reaction [Triamcinolone Acetonide results in increased expression of CYP3A5 mRNA] CTD PMID:24555085 trichostatin A multiple interactions ISO RGD:1348646 6480464 trichostatin A inhibits the reaction [Pregnenolone Carbonitrile results in increased expression of CYP3A11 mRNA] CTD PMID:26883953 triclosan increases expression EXP 6480464 Triclosan results in increased expression of CYP3A9 mRNA CTD PMID:22659317 triclosan increases expression ISO RGD:1348646 6480464 Triclosan results in increased expression of CYP3A5 mRNA CTD PMID:29849464 triptonide increases expression ISO RGD:731686 6480464 triptonide results in increased expression of CYP3A13 mRNA CTD PMID:33045310 Tris(1-aziridinyl)phosphine oxide affects export ISO RGD:1348646 6480464 CYP3A5 gene SNP affects the export of Triethylenephosphoramide CTD PMID:19076156 Tris(1-aziridinyl)phosphine oxide affects response to substance ISO RGD:1348646 6480464 CYP3A5 protein affects the susceptibility to Triethylenephosphoramide CTD PMID:19076156 troglitazone decreases expression ISO RGD:1348646 6480464 troglitazone results in decreased expression of CYP3A5 CTD PMID:15618651 troglitazone increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of troglitazone CTD PMID:19356091 troleandomycin multiple interactions ISO RGD:1348646 6480464 Troleandomycin inhibits the reaction [CYP3A5 protein affects the metabolism of Alfentanil] CTD PMID:15731592 troleandomycin decreases activity ISO RGD:1348646 6480464 Troleandomycin results in decreased activity of CYP3A5 protein CTD PMID:15557344 undecane decreases expression EXP 6480464 undecane results in decreased expression of CYP3A13 protein CTD PMID:17337753 valdecoxib increases expression EXP 6480464 valdecoxib results in increased expression of CYP3A9 mRNA CTD PMID:24136188 valproic acid decreases expression ISO RGD:1348646 6480464 Valproic Acid results in decreased expression of CYP3A5 mRNA CTD PMID:29154799 valsartan affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene affects the susceptibility to Valsartan CTD PMID:22149319 verapamil decreases activity ISO RGD:1348646 6480464 Verapamil results in decreased activity of CYP3A5 protein CTD PMID:15689501 verapamil decreases expression EXP 6480464 Verapamil results in decreased expression of CYP3A9 mRNA CTD PMID:17973928 vincristine increases metabolic processing ISO RGD:1348646 6480464 CYP3A5 protein results in increased metabolism of Vincristine CTD PMID:21225912 vincristine multiple interactions ISO RGD:1348646 6480464 [CYP3A5 gene polymorphism results in increased activity of CYP3A5 protein] which results in increased metabolism of Vincristine CTD PMID:21225912 vitamin E decreases expression ISO RGD:1348646 6480464 Vitamin E results in decreased expression of CYP3A5 mRNA CTD PMID:19244175 warfarin affects response to substance ISO RGD:1348646 6480464 CYP3A5 gene polymorphism affects the susceptibility to Warfarin, CYP3A5 protein affects the susceptibility to Warfarin CTD PMID:19752777 XAV939 multiple interactions ISO RGD:1348646 6480464 [[ascorbate-2-phosphate co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA, [[Ascorbic Acid co-treated with Chir 99021 co-treated with XAV939 co-treated with BMP4 protein co-treated with FGF1 protein co-treated with WNT3A protein co-treated with HGF protein] co-treated with [INHBA protein binds to INHBA protein]] results in increased expression of CYP3A5 mRNA CTD PMID:34480604 zinc atom multiple interactions ISO RGD:1348646 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of CYP3A5 mRNA CTD PMID:18593933 zinc atom increases expression EXP 6480464 Zinc deficiency results in increased expression of CYP3A9 mRNA CTD PMID:11705462 zinc(0) multiple interactions ISO RGD:1348646 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of CYP3A5 mRNA CTD PMID:18593933 zinc(0) increases expression EXP 6480464 Zinc deficiency results in increased expression of CYP3A9 mRNA CTD PMID:11705462 zoledronic acid increases expression ISO RGD:1348646 6480464 zoledronic acid results in increased expression of CYP3A5 mRNA CTD PMID:24714768
